WASHINGTON, DC—Bates White is pleased to announce that Dr. Richard Manning has joined the firm as a Partner in the Healthcare Practice. Dr. Manning was previously a senior executive at Merck & Co., Inc. and Pfizer, Inc. where he oversaw public policy analysis and strategy in domestic and international pharmaceutical markets.
Dr. Manning has an extensive background providing analysis and thought leadership in public policy and economics for the pharmaceutical, biotechnology, and healthcare industries. His career includes 14 years as a senior executive at worldwide pharmaceutical companies where he led economic analysis and strategy development to shape business practices related to public policy issues. His extensive expertise incorporates a broad range of talents from innovative business strategy development and rigorous economic analysis to superb writing and public speaking skills.
Eric Gaier, Chair of the Bates White Healthcare Practice, commented, “Richard Manning is the perfect addition to our Healthcare Practice. His notable public policy experience will strengthen a growing area of focus for us. Richard broadens and deepens our team of experts and enhances the value we bring to pharmaceutical and healthcare clients. It’s a pleasure to welcome him to our firm.”
Dr. Manning said, “I am pleased to join the esteemed group of economists at Bates White who are recognized for their successful track record of client support in the pharmaceutical and healthcare industries. This is an exceptional opportunity for me, and I look forward to furthering the group’s work in these areas.”
Prior to joining Bates White, Dr. Manning was Executive Director of Global Public Policy at Merck & Co., Inc. Previously, he was Director in the Advisory Strategy Group at PricewaterhouseCoopers where he specialized in strategic partnerships, deal activity, and empirical economic analysis for several pharmaceutical clients. Dr. Manning was also Senior Director of Economic and Policy Research at Pfizer, Inc. During his 12 years with Pfizer, his team provided economic analysis for strategic decision-making on public policy issues. His department also established and maintained Pfizer’s link to outside academic economists to foster research on key public policy issues. Dr. Manning joined Pfizer in 1997 after leaving Brigham Young University where he had been a professor of economics since 1990.